Methods
coronary artery disease
TYPE 2 DIABETES, CORONARY ARTERY DISEASE
A total of 97 patients with type 2 diabetes and coronary artery disease were randomized to empagliflozin (10 mg/d) or matching placebo for 6 months. The study cohort was divided into those whose baseline LVMi was ≤ 60 g/m